Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis.
Yun-Kyoung SongJaehee LeeJunwoo JoJin Won KwonPublished in: RMD open (2024)
Patients with RA using JAK inhibitors have a significantly lower risk of active tuberculosis than bDMARD users in South Korea; however, patients with RA having LTBI are equally at risk regardless of the treatment received (JAK inhibitor vs bDMARD). Therefore, vigilant tuberculosis monitoring, especially in patients with low adherence to tuberculosis preventive therapy, is essential.
Keyphrases
- rheumatoid arthritis
- mycobacterium tuberculosis
- pulmonary tuberculosis
- hiv aids
- disease activity
- risk assessment
- ankylosing spondylitis
- adverse drug
- interstitial lung disease
- emergency department
- stem cells
- type diabetes
- systemic lupus erythematosus
- metabolic syndrome
- combination therapy
- human immunodeficiency virus
- antiretroviral therapy